Logo

KRAS Biomarkers

News and reporting on KRAS biomarkers.

Quest Diagnostics to Offer Agilent Companion Test for Mirati Therapeutics NSCLC Treatment

Agilent's companion diagnostic for Mirati's non-small cell lung cancer treatment Krazati will be available through Quest's national healthcare network.

Pillar Biosciences Receives China Approval for Colon Cancer Companion Diagnostic Assay

The OncoReveal Dx Colon Cancer Assay is intended for use on the Illumina MiSeq Dx, and now has approvals in China, the US, and Europe.

Amoy Diagnostics, Amgen Partner on Lung Cancer CDx Development for Lumakras in Japan

Amoy Diagnostics will develop its PCR-based panel as a companion diagnostic in Japan to screen NSCLC patients for Amgen's KRAS G12C inhibitor.

FDA Approves Amgen's Lumakras for NSCLC Alongside Companion Tests From Guardant Health, Qiagen

The approval makes Lumakras the first inhibitor of KRAS, once considered "undruggable," to reach the market for KRAS-mutated NSCLC.

Qiagen, Mirati Therapeutics Partner to Develop KRAS Companion Test for NSCLC Drug

The tissue-based test will identify cancer patients who may benefit from adagrasib, Mirati's investigational oral small molecule inhibitor of KRAS G12C.

Apr 19, 2021

Amgen, NeoGenomics Partner to Expand Biomarker Testing Access in NSCLC

Aug 13, 2020

Strata, Mirati Therapeutics Partner on Tumor-Agnostic Clinical Trial of Novel KRAS G12C Inhibitor

Apr 27, 2020

Amid COVID-19, Lower Cancer Diagnosis Rates Mean Fewer Patients Getting Molecular Tests, Treatment
Premium

Feb 13, 2020

Genetron Health Obtains Regulatory Approval in China for NGS Instrument, Lung Cancer Panel

Jan 27, 2020

Colon Cancer Biomarker Undertesting Rates in Real-World Data Points to Precision Oncology Barriers
Premium

Jan 14, 2020

Qiagen, Amgen Collaborate to Develop CDx for Investigational NSCLC Drug

Sep 23, 2019

Global Survey Reveals Suboptimal Molecular Testing Access in Lung Cancer Despite Broad Guidelines
Premium

Aug 2, 2019

Comparison of KRAS Liquid Biopsy Kits Confirms Differences at Low Mutant Allele Fraction

Jun 6, 2019

TAPUR Study Investigators Report First Positive Findings, Pursuing Tissue-Agnostic Cohorts
Premium

May 29, 2019

CRISPR Framework Helps Identify Combination Therapies for Optimal Targeting of KRAS Mutant

Feb 26, 2019

Thermo Fisher Scientific Oncomine Dx Target Test Gets Expanded Regulatory Approval in Japan

Jan 29, 2019

AmoyDx, Sanomics Ink Deal for Multigene Mutation Detection Kit

Oct 31, 2018

Lung Cancer Panel From PlexBio Receives CE Mark

Oct 17, 2018

Thermo Fisher Scientific Gets CE-IVD Mark for NGS Cancer Test

Sep 27, 2018

UK Group Develops Cancer Liquid Biopsy Assay to Detect Low-Level Mutations
Premium

Oct 17, 2017

AstraZeneca Publishes Head-to-Head Study of 13 KRAS Mutation Detection Technologies
Premium

Jan 6, 2017

Two Pore Guys Collaborating With UCSF on Point-of-Care Liquid Biopsy

Dec 15, 2016

Biocartis Gets CE Mark for Idylla NRAS-BRAF Mutation Test

Oct 3, 2016

KRAS-Driven Tumor Growth Inhibited by MicroRNA

May 13, 2016

Colorectal Cancer Patients' Cetuximab Response Can Be Discerned From FCGR2A Genotype
Premium

Breaking News
The Scan

Nucleotide Base Detected on Near-Earth Asteroid

Among other intriguing compounds, researchers find the nucleotide uracil, a component of RNA sequences, in samples collected from the near-Earth asteroid Ryugu, as they report in Nature Communications.

Clinical Trial Participants, Investigators Point to Importance of Clinical Trial Results Reporting in Canadian Study

Public reporting on clinical trial results is crucial, according to qualitative interviews with clinical trial participants, investigators, and organizers from three provinces appearing in BMJ Open.

Old Order Amish Analysis Highlights Autozygosity, Potential Ties to Blood Measures

Researchers in BMC Genomics see larger and more frequent runs-of-homozygosity in Old Order Amish participants, though only regional autozygosity coincided with two blood-based measures.

Suicidal Ideation-Linked Loci Identified Using Million Veteran Program Data

Researchers in PLOS Genetics identify risk variants within and across ancestry groups with a genome-wide association study involving veterans with or without a history of suicidal ideation.